Evotec (EVO) Set to Release Earnings on Thursday

Evotec (NASDAQ:EVO) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.1783) per share and revenue of $165.19 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Evotec Stock Performance

EVO stock opened at $1.55 on Wednesday. Evotec has a 1-year low of $1.33 and a 1-year high of $4.09. The firm has a fifty day moving average price of $1.63 and a two-hundred day moving average price of $2.50. The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 25th. Berenberg Bank downgraded shares of Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Evotec in a research note on Wednesday, October 14th. Finally, TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, July 15th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Evotec currently has an average rating of “Hold” and a consensus target price of $3.00.

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.